![Martine Zimmermann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 1 Mio $ am 31.05.2026
Martine Zimmermann currently works at Ligand Pharmaceuticals, Inc., as Independent Director from 2023 and Inventiva SA, as EVP-Regulatory Affairs & Quality Assurance from 2025.
Dr. Zimmermann also formerly worked at Caelum Biosciences, Inc., as Director from 2019 to 2021, Alexion Pharmaceuticals, Inc., as Senior VP & Head-Global Regulatory Affairs from 2016 to 2023, and Ipsen Biopharmaceuticals, Inc., as SVP, Head-Regulatory Affairs, R&D Quality.
Dr. Zimmermann received her doctorate degree from the University of Strasbourg and doctorate degree from Louis Pasteur University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.06.2026 | 5.097 ( 0,03 % ) | 1 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| INVENTIVA | General Counsel | 09.07.2025 |
| LIGAND PHARMACEUTICALS INCORPORATED | Direktor/Vorstandsmitglied | 26.09.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 01.02.2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that develops treatments for AL amyloidosis, rare and life-threatening hematologic disorders | Direktor/Vorstandsmitglied | 01.01.2021 |
Ipsen Biopharmaceuticals, Inc.
 Ipsen Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company | General Counsel | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 7 |
|---|---|
Ligand Pharmaceuticals, Inc.
 Ligand Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and sells drug development technologies | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
University of Strasbourg
 University of Strasbourg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ipsen Biopharmaceuticals, Inc.
Ipsen Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company | Health Technology |
Inventiva SA
 Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that develops treatments for AL amyloidosis, rare and life-threatening hematologic disorders | Health Technology |
Louis Pasteur University
 Louis Pasteur University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
Wählen Sie MarketScreener 
